Correlation Between Embecta Corp and Rapport Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Embecta Corp and Rapport Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Embecta Corp and Rapport Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Embecta Corp and Rapport Therapeutics Common, you can compare the effects of market volatilities on Embecta Corp and Rapport Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Embecta Corp with a short position of Rapport Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Embecta Corp and Rapport Therapeutics.

Diversification Opportunities for Embecta Corp and Rapport Therapeutics

-0.75
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Embecta and Rapport is -0.75. Overlapping area represents the amount of risk that can be diversified away by holding Embecta Corp and Rapport Therapeutics Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Rapport Therapeutics and Embecta Corp is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Embecta Corp are associated (or correlated) with Rapport Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Rapport Therapeutics has no effect on the direction of Embecta Corp i.e., Embecta Corp and Rapport Therapeutics go up and down completely randomly.

Pair Corralation between Embecta Corp and Rapport Therapeutics

Given the investment horizon of 90 days Embecta Corp is expected to under-perform the Rapport Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Embecta Corp is 2.89 times less risky than Rapport Therapeutics. The stock trades about -0.02 of its potential returns per unit of risk. The Rapport Therapeutics Common is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  1,327  in Rapport Therapeutics Common on October 18, 2025 and sell it today you would earn a total of  1,359  from holding Rapport Therapeutics Common or generate 102.41% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Embecta Corp  vs.  Rapport Therapeutics Common

 Performance 
       Timeline  
Embecta Corp 

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Embecta Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's fundamental drivers remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.
Rapport Therapeutics 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Rapport Therapeutics Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Rapport Therapeutics may actually be approaching a critical reversion point that can send shares even higher in February 2026.

Embecta Corp and Rapport Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Embecta Corp and Rapport Therapeutics

The main advantage of trading using opposite Embecta Corp and Rapport Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Embecta Corp position performs unexpectedly, Rapport Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rapport Therapeutics will offset losses from the drop in Rapport Therapeutics' long position.
The idea behind Embecta Corp and Rapport Therapeutics Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Complementary Tools

Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance